FY2026 Q3 results: Revenue ¥15.09B (YoY -¥1.97B, -11.5%), Operating Loss ¥5.63B (YoY -¥2.32B, loss widened), Ordinary Loss ¥5.54B (YoY -¥2.24B, loss widened), Net Loss ¥5.56B (YoY -¥2.06B, loss widened). Although the gross margin was 55.4%, indicating sustained earning potential of products/services, SG&A of ¥13.99B weighed on revenue and resulted in an operating loss. Lower revenue and profits were mainly driven by fewer JaCE burn cases in the Regenerative Medicine Products Business and the deferral of contract cases to next fiscal year in the Regenerative Medicine Contract Services Business. On the other hand, Jack OA’s indication expansion completed insurance listing in January 2026 and sales commenced, while the Labsite Business grew +20.3% YoY on progress in Europe. With cash and cash equivalents of ¥33.36B and an equity ratio of 89.4%, the financial base is solid, but improving operating efficiency is an urgent priority.
[Revenue] Revenue decreased by ¥1.97B from ¥17.06B in the prior-year period to ¥15.09B (-11.5%). The core Regenerative Medicine Products Business posted ¥9.56B (-9.5% YoY), impacted by fewer JaCE burn cases. The Regenerative Medicine Contract Services Business recorded ¥3.46B (-27.5% YoY), a significant decline due mainly to the absence of last year’s one-off revenue from a specific customer in general client contracts and the deferral to next fiscal year of milestone recognition for the Teijin contract. The Labsite Business was ¥2.07B (+20.3% YoY), tracking strongly on expansion to five companies with subscriptions in Europe and the start of sales to the U.S. Institute for In Vitro Sciences.
[Profit and loss] Gross Profit was ¥8.35B (¥9.52B in the prior year) with a Gross Margin of 55.4% (55.8% in the prior year), sustaining product profitability. SG&A increased by ¥1.16B to ¥13.99B (¥12.83B in the prior year), and the SG&A-to-Revenue ratio deteriorated to 92.7% (75.2% in the prior year). Operating Loss was ¥5.63B (¥-3.31B in the prior year), widening by ¥2.32B. The increase in SG&A is presumed to reflect upfront investments for Jack OA insurance listing, Jasmine site expansion, and strengthened overseas rollout, as well as enhancements in employee compensation. Non-operating income/expenses were minor, resulting in an Ordinary Loss of ¥5.54B and, with no special items disclosed, a Net Loss of ¥5.56B. The pattern reflects revenue decline with higher SG&A leading to lower revenue and larger losses.
Regenerative Medicine Products Business: Revenue ¥9.56B, Operating Income ¥0.06B (the prior year did not disclose operating income even in a growth period, so the change is unknown). This is the largest segment (63.4% of revenue). Although revenue decreased due to fewer JaCE burn cases, the number of facilities capable of handling Jasmine expanded to 11, and contracts for OA-capable facilities progressed to 52 following completion of Jack OA insurance listing, building a foundation for growth. The profit margin is extremely low at 0.6%, making scale expansion and fixed-cost absorption key going forward.
Regenerative Medicine Contract Services Business: Revenue ¥3.46B, Operating Income ¥1.86B. With an operating margin of 53.6%, this is a highly profitable business. Despite lower revenue YoY, margins remained elevated. Progress is being made in building a backlog of long-term contracted cases, including the execution of a commercial manufacturing services contract with AlliedCel. While milestones were deferred, causing short-term revenue decline, the profit structure remains sound.
Labsite Business: Revenue ¥2.07B, Operating Income ¥0.46B. With an operating margin of 22.4%, this is a stable earnings driver. The business is on a growth trajectory at +20.3% YoY due to expanded subscriptions in Europe and the start of sales in the U.S. Consideration is underway for establishing a European base, implying medium-term growth potential.
Against a company-wide Operating Loss of ¥5.63B, total segment Operating Income is ¥2.38B, implying unallocated costs such as headquarters expenses and R&D expenses of roughly ¥8B. Balancing growth investments is an issue.
Profitability: ROE -10.6% (prior year not disclosed; negative due to ongoing net loss), Operating Margin -37.3% (prior year -19.4%), Net Margin -36.9% (prior year -20.3%), remaining in the red. Gross Margin of 55.4% (prior year 55.8%) remains high.
Cash quality: Operating Cash Flow details were not disclosed, so OCF/Net Income cannot be calculated. FCF is also undisclosed. Cash and cash equivalents of ¥33.36B represent 56.6% of total assets, ensuring liquidity despite continued losses.
Investment efficiency: Capex and depreciation details were not disclosed, so the Capex/Depreciation multiple cannot be calculated.
Financial soundness: Equity Ratio 89.4% (89.4% in the prior year), stable at a high level; Current Ratio 700.2% (701.9% in the prior year), indicating extremely strong short-term payment capacity. Debt-to-Capital ratio is 0.12x, indicating low leverage.
As details of Operating CF, Investing CF, and Financing CF were not disclosed, cash flow analysis is limited. However, cash and cash equivalents edged down only slightly from ¥33.53B to ¥33.36B (-¥0.17B, -0.5%), moving sideways. Despite ongoing losses, cash did not decline significantly, suggesting some cash generation via working capital improvements and financing. Accounts receivable decreased from ¥5.44B to ¥3.55B (-¥1.89B, -34.7%), which, in addition to normal fluctuations due to lower sales, may reflect collection progress. Accounts payable increased from ¥0.25B to ¥0.39B (+¥0.14B, +57.8%), indicating signs of payment term adjustments. These likely contributed to working capital improvement. FCF calculation requires capex, which is undisclosed. There is no mention of dividends or share buybacks, suggesting minimal financing CF. While cash generation is below standard, the ample cash balance limits short-term liquidity risk.
The difference between Ordinary Loss of ¥5.54B and Net Loss of ¥5.56B is ¥0.02B and minor, with no disclosure of extraordinary gains/losses, effectively aligning the two. Earnings quality can be assessed at the ordinary income level. Ordinary Loss is slightly smaller than Operating Loss (¥5.54B vs. ¥5.63B), implying non-operating income exceeded non-operating expenses. Details of non-operating income are not disclosed, but its scale is less than 1% of revenue and has limited impact on the earnings structure. Since OCF is undisclosed, earnings quality cannot be evaluated by comparing OCF with net income. However, the decline in accounts receivable suggests progress in cash realization of profits, confirming a certain level of earnings quality. There were no temporary factors affecting P/L; the main cause of losses is structurally high SG&A.
Full-year guidance was revised downward to Revenue ¥22.10B, Operating Loss ¥5.50B, Ordinary Loss ¥5.40B, and Net Loss ¥5.40B. Progress against Q3 cumulative results: Revenue 68.3% (vs. standard 75%, -6.7pt) and Operating Loss 102.4% (already exceeding full-year guidance). The overrun in operating loss is mainly due to upfront SG&A through Q3, with expectations for loss reduction in Q4 through revenue uplift from Jack OA insurance listing effects and tighter SG&A control. YoY revenue is unchanged from the prior guidance at -10%, while the operating loss width was revised from ¥5.00B to ¥5.50B, a ¥0.50B widening. Key factors are fewer JaCE burn cases and the deferral of contracted cases to next fiscal year. Management has reset a target to return to profitability next fiscal year (FY2027), positioning Jack OA indication expansion as the primary earnings driver, with a mid-term goal of 1,000 cases per year and approximately ¥30B in revenue within several years.
No dividends were declared for either interim or year-end; the company continues a no-dividend policy. Payout Ratio is not applicable. There is no mention of share buybacks; hence, Total Return Ratio does not apply. With ongoing losses, dividend distribution appears unlikely; turnaround and a return to profitability take priority. While holding ¥33.36B in cash and cash equivalents, shareholder returns are expected to be deferred until earnings improve through SG&A reduction and revenue recovery. Retained earnings improved from ¥-19.22B to ¥-5.56B, a ¥13.66B improvement, due to deficit compensation via reductions of capital stock and capital surplus of ¥9.61B each (implemented in May 2025). A dividend policy may be considered after achieving profitability.
[Short term]
[Long term]
[Industry positioning] (Reference information; our research) Profitability: Operating Margin -37.3% (industry median 7.3%, IQR 4.6%–12.0%), 44.6pt below the industry median; extremely low within manufacturing. Net Margin -36.9% (industry median 5.4%, IQR 3.5%–8.9%), 42.3pt below the industry median. ROE -10.6% (industry median 4.9%, IQR 2.8%–8.2%), 15.5pt below the industry median, placing profitability near the bottom of the industry. While Gross Margin is high at 55.4%, heavy SG&A depresses margins sharply.
Soundness: Equity Ratio 89.4% (industry median 63.9%, IQR 51.5%–72.3%), 25.5pt above the median; upper-tier within manufacturing. Current Ratio 7.00x (industry median 2.67x, IQR 2.00–3.56x), 4.33x above the median; top-tier short-term payment capacity. Net debt/EBITDA multiple is not calculable due to negative EBITDA. Financial soundness is extremely high.
Efficiency: Return on Assets -9.4% (industry median 3.3%, IQR 1.8%–5.1%), 12.7pt below the median; capital efficiency is near the bottom of the industry. Revenue growth rate -11.5% (industry median 2.8%, IQR -0.9%–7.9%), 14.3pt below the median; growth is also inferior within the industry.
Industry: Manufacturing (65 companies), comparison period: FY2025 Q3, source: our compilation
Risk of continued decline in JaCE burn cases: The YoY decrease in Q3 was a key driver of lower revenue. Management assesses that case volume fluctuates historically and that this is transitory, but revenue pressure may persist until awareness initiatives bear fruit. The specific number of burn cases decreased in FY2025 Q3 is undisclosed, but the impact on the core product’s revenue is significant.
Risk of continued losses due to elevated SG&A: SG&A of ¥13.99B equals 92.7% of revenue of ¥15.09B, which is excessive. While upfront investments (Jack OA insurance listing, Jasmine site expansion, overseas rollout, R&D) are necessary at this stage, delayed SG&A control would make it difficult to achieve profitability. Achieving profitability next fiscal year requires both SG&A reduction and revenue recovery.
Risk of delays in monetizing development pipelines and contracted projects: Filing for approval of Allo-JaCE03 is planned within this fiscal year, but timing risk exists. There is a track record of milestone recognition in the Regenerative Medicine Contract Services Business slipping to the next fiscal year, implying high uncertainty in the timing of monetization. Case volumes for Jasmine tracking below plan and fewer new patients for Nepic Ocular are also medium-term risk factors.
Progress in monetizing Jack OA indication expansion is the most important monitoring item: insurance listing was completed in January 2026 with contracts at 52 facilities. The pace of case accumulation and average selling price from Q4 onward will drive full-year and next-year results. With management targeting 1,000 cases per year and approximately ¥30B in revenue within several years, quarterly disclosure of case counts is key for investment decisions.
Confirming room for structural improvement in SG&A: SG&A is an excessive 93% of revenue and the main cause of operating losses. It is necessary to assess the nature of upfront investments (discretionary/fixed) and potential for reduction. To achieve profitability next fiscal year, the SG&A ratio needs to be reduced below 70% in parallel with revenue growth, testing room for efficiencies in personnel expenses, R&D, and marketing, as well as management’s cost control capability.
Sustainability of high profitability in the Regenerative Medicine Contract Services Business: With an operating margin of 53.6%, profitability is extremely high. If long-term contracts with companies like AlliedCel accumulate, the contribution to overall earnings will be substantial. Greater transparency in contract terms (milestones, fixed/variable revenue structures) and timing of revenue recognition will aid in assessing business stability.
This report is an automatically generated earnings analysis produced by AI integrating XBRL financial statement data and PDF earnings presentation materials. It does not constitute a recommendation to invest in any particular security. The industry benchmarks are reference information compiled by us based on publicly available financial data. Investment decisions are your own responsibility; consult a professional as needed before investing.